Vera Therapeutics (NASDAQ:VERA) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Vera Therapeutics (NASDAQ:VERA) posted its earnings results on Monday. The company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.60) by $0.08, FiscalAI reports. During the same quarter last year, the company posted ($1.20) EPS.

Vera Therapeutics Price Performance

Shares of VERA opened at $31.58 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. The company has a market cap of $2.27 billion, a P/E ratio of -5.70 and a beta of 0.92. Vera Therapeutics has a 12 month low of $19.28 and a 12 month high of $56.05. The stock has a fifty day moving average price of $36.53 and a 200 day moving average price of $38.93.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total value of $1,956,375.00. Following the sale, the chief executive officer owned 151,994 shares in the company, valued at approximately $6,429,346.20. This trade represents a 23.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of VERA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Vera Therapeutics by 7.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock worth $753,000 after purchasing an additional 2,210 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Vera Therapeutics by 22.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock valued at $2,354,000 after acquiring an additional 17,907 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Vera Therapeutics by 297.1% in the first quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock valued at $999,000 after acquiring an additional 62,678 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Vera Therapeutics by 550.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock valued at $7,316,000 after purchasing an additional 262,805 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of Vera Therapeutics by 1.7% in the second quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock valued at $1,188,000 after buying an additional 825 shares during the period. 99.21% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. The Goldman Sachs Group reissued a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Jefferies Financial Group reiterated a “buy” rating and issued a $60.00 price target on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. TD Cowen lifted their price target on shares of Vera Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Finally, Wedbush lifted their price target on Vera Therapeutics from $35.00 to $43.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $84.58.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.